Latham & Watkins advises 4D Molecular Therapeutics on the deal.Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license agreement…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Pietro Martinoia
…
This content is for Standard 1 Year members only. LoginJoin Now